| 1 |
34809976 | Histone deacetylase inhibition by suberoylanilide hydroxamic acid: a therapeutic approach to treat human uterine leiomyoma. | 2022 Feb |
2 |
| 2 |
30307360 | The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. | 2019 |
1 |
| 3 |
30424705 | A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. | 2019 May |
1 |
| 4 |
31189612 | Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. | 2019 Aug |
1 |
| 5 |
30091530 | ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid. | 2018 Sep |
1 |
| 6 |
27761814 | Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation. | 2017 |
3 |
| 7 |
27911270 | SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study. | 2017 Jan 10 |
1 |
| 8 |
28123594 | Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. | 2017 |
2 |
| 9 |
26287365 | Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling. | 2015 |
1 |
| 10 |
26681199 | Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro. | 2015 Dec 17 |
4 |
| 11 |
23686769 | Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. | 2013 Aug |
1 |
| 12 |
22159450 | Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells. | 2012 Mar |
1 |
| 13 |
22749963 | Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability. | 2012 Sep 1 |
16 |
| 14 |
21542457 | Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. | 2011 |
1 |
| 15 |
21931726 | The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. | 2011 |
2 |
| 16 |
19440035 | Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. | 2009 Jul |
1 |
| 17 |
18166465 | Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. | 2008 Mar 15 |
1 |
| 18 |
17417771 | Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. | 2007 Aug 1 |
1 |
| 19 |
17606765 | Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. | 2007 Oct 1 |
10 |
| 20 |
16343270 | Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. | 2006 Jan |
1 |
| 21 |
15661398 | Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. | 2005 Jan |
1 |